FDA approves Incyte’s Pemazyre for rare bile duct cancer –

The FDA has approved Incyte’s Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile duct.

At the moment the main treatment options for cholangiocarcinoma are surgery, stent insertion, chemotherapy, and radiotherapy.

Pemazyre provides a new option for adults with cholangiocarcinoma that is unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

The FDA granted a faster accelerated approval based on figures from the single-arm FIGHT-202 study showing overall response rate and duration of response, with continued approval depending on data from a larger trial.

FIGHT-202 was a multi-centre, open-label study and showed that in patients with FGFR2 fusions or rearrangements, Pemazyre produced an overall response rate of 36%, the primary endpoint.

It also met secondary endpoint with a duration of response of 9.1 months.

Incyte said warnings and precautions for Pemazyre include eye problems such as dry or inflamed eyes, inflamed cornea, increased tears and a disorder of the retina; high levels of phosphate in the blood; and, for women who are pregnant, a risk of harm to the unborn baby or loss of pregnancy.

The FDA had granted Pemazyre Breakthrough Therapy status, allowing extra help during clinical development, Orphan Drug designation, and granted a faster Priority Review lasting up to six months instead of the standard 10 month period.

Cholangiocarcinoma is a rare cancer that forms in the bile duct. It is classified based on its anatomical origin: intrahepatic cholangiocarcinoma (iCCA) occurs in the bile duct inside the liver and extrahepatic cholangiocarcinoma occurs in the bile duct outside the liver.

Patients with cholangiocarcinoma are often diagnosed at a late or advanced stage when the prognosis is poor.

The incidence of cholangiocarcinoma varies regionally and ranges between 0.3-3.4 per 100,000 in North America and Europe.

FGFR2 fusions or rearrangements occur almost exclusively in iCCA, where they are observed in 10-16% of patients.

Regulators from the European Medicines Agency (EMA) have also begun their review of Pemazyre.

Source link

Infrared Pocket Thermometer, retractable sensor with protective doors, NEW

Extend the Census Deadline to Protect Vulnerable Children